News | Oncology Diagnostics | October 30, 2017

Laser Scanner Detects Skin Cancer in Less Than 30 Seconds

A team of European scientists has developed the world’s first cancer scanner that detects blood vessels grown by a malignant melanoma with an infrared laser beam in 30 seconds

Laser Scanner Detects Skin Cancer in Less Than 30 Seconds

Image courtesy of VivoSight

cancer detection scanning patient

Image courtesy of VivoSight

 Photonics VivoSightDX OCT cancer detection screen

Image courtesy of VivoSight

October 30, 2017 — Current skin cancer diagnosis can last a number of weeks and be very upsetting. However, a new imaging system developed by a group of European scientists could dramatically speed up the process and reduce the need for debilitating sentinel-lymph node biopsies by placing real-time cancer diagnosis in the hands of a dermatologist.

Multiple stages of skin cancer diagnosis can involve visiting a GP, being sent to a dermatologist for a skin biopsy, waiting for laboratory analysis, having a sentinel lymph node biopsy under general anaesthetic, and then having more tests if the cancer has spread.

Now, using a handheld laser, a specialist can actually see under the skin at depths of 1 mm by creating a 3-D color image of the microscopic blood vessels in a process that takes around 30 seconds.

Employing a new and advanced version of optical coherence tomography (OCT), a photonics technique more commonly used in retina scans, the scanner captures 3-D images of the micro-structures under the skin with a harmless infrared laser beam.

Since melanomas need oxygen to grow and survive, they grow their own blood vessels. As the cancer develops and becomes more malignant, they become increasingly distorted and malformed, differing in appearance from healthy vessels.

Being able to detect and see these vessels in a suspicious lesion in real time has never been possible, until now, opening the possibility for dermatologists to make treatment decisions in an unrivalled timeframe.

Over 55,500 people in the world died from malignant melanoma of the skin in 2012 alone. While 2,459 deaths from melanoma skin cancer were recorded in the United Kingdom in 2014, an estimated 9,730 people will die of melanoma in the United States in 2017.

Melanomas produce their own blood vessels to feed and grow the tumor, so by revealing the microstructures in 3-D pictures the scanner show doctors how the cancer has developed.

A specialist can potentially determine on the spot, whether simply cutting it out is sufficient for a cure or whether further treatment with cancer drugs will be needed.

With their new device called VivoSight on the market, the European team ADVANCE (Automatic Detection of VAscular Networks for Cancer Evaluation) is aiming to reduce the time for treatment decision from a number of weeks to a matter of seconds, while removing the invasive nature of the appointment.

U.K. project leader Jon Holmes of Michelson Diagnostics Ltd, a key partner in the ADVANCE consortium, explained, “Every melanoma above a certain thickness could have spread to other parts of the body. At present, all patients with such melanomas have to wait for a sentinel lymph node biopsy performed in a hospital under general anesthesia to find out if it is spreading. This can take weeks to perform, is very expensive and can be debilitating for the patient.”

The ADVANCE team has employed a variant of OCT in its scanner called speckle-variance OCT or dynamic OCT (D-OCT), an advancement of OCT that is ideal for capturing movement.

Studying the ‘speckle’ or flicker of light patterns created by moving blood cells, the imaging device takes around four frames per second and compiles the images so that a clinician may tell where something has moved on the image from frame to frame.

“Using D-OCT we can see movement of blood against the solid tissue structures, something we have never been able to do before in a clinical setting. It’s like looking out at night and seeing cars’ headlights flowing along a motorway, only at depths of nanometers under the skin,” said Holmes.

While a sentinel node biopsy can cost in excess of €10,000 (~$13,000 U.S.), and with many hospitals performing hundreds per year, there is a growing concern and a need to find an alternative when over 80 percent of these operations turn out to be clear of any malignant growth, according to Holmes.

As well as its use in skin cancer diagnosis, the ability to see blood vessel networks with the ADVANCE technology has created a number of useful spin-off benefits.

“The scanner can image the blood vessels in healing wounds. This may have application for treatment of leg and foot chronic ulcers, when doctors want to know whether a wound is healing or requires a change in treatment, potentially reducing the number of amputations,” said Holmes. He added,

“ADVANCE technology may also help with burn victims, being able to give a doctor a quicker response time than the standard 15 days to determine whether a patient’s skin is healing and whether or not to give a skin graft.”

For more information: www.photonics21.org

Related Content

IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017.

IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017, and who had health records for at least one year prior to the mammogram. The algorithm was trained on 9,611 mammograms. Image courtesy of Radiology.

Feature | Artificial Intelligence | July 19, 2019 | Michal Chorev
Breast cancer is the global leading cause of cancer-related deaths in women, and the most commonly diagnosed cancer...
Paragon Biosciences Launches Qlarity Imaging to Advance FDA-cleared AI Breast Cancer Diagnosis System

Qlarity Imaging’s software is used to assist radiologists in the assessment and characterization of breast lesions. Imaging features are synthesized by an artificial intelligence algorithm into a single value, the QI score, which is analyzed relative to a database of reference abnormalities with known ground truth. Image courtesy of Business Wire.

Technology | Artificial Intelligence | July 18, 2019
Paragon Biosciences LLC announced the launch of its seventh portfolio company, Qlarity Imaging LLC, which was founded...
New Lung Ambition Alliance Aims to Double Five-year Lung Cancer Survival by 2025
News | Lung Cancer | July 17, 2019
The International Association for the Study of Lung Cancer (IASLC), Guardant Health, the Global Lung Cancer Coalition (...
FDA Clears Koios DS Breast 2.0 AI-based Software
News | Ultrasound Women's Health | July 11, 2019
Koios Medical announced its second 510(k) clearance from the U.S. Food and Drug Administration (FDA).
SimonMed Imaging Implements ProFound AI for 3-D Tomosynthesis
News | Mammography | July 10, 2019
Arizona-based SimonMed Imaging announced their implementation of the first U.S. Food and Drug Administration (FDA)-...
TeraRecon Unveils iNtuition AI Data Extractor
News | Advanced Visualization | July 03, 2019
Artificial Intelligence (AI) and advanced visualization company TeraRecon announced its new iNtuition AI Data Extractor...
Therapixel Appoints Matthieu Leclerc-Chalvet as CEO
News | Artificial Intelligence | July 03, 2019
Artificial intelligence (AI) breast cancer screening specialist Therapixel announced the appointment of Matthieu...
A 3-D printed model (left) and a model constructed in augmented reality (right), both of a kidney with a tumor. In both models, the kidney is clear; the tumor is visible in purple on the AR model and in white on the 3-D printed model.

A 3-D printed model (left) and a model constructed in augmented reality (right), both of a kidney with a tumor. In both models, the kidney is clear; the tumor is visible in purple on the AR model and in white on the 3-D printed model. Photo courtesy of Nicole Wake, Ph.D.

Feature | Advanced Visualization | July 02, 2019 | By Jeff Zagoudis
Three-dimensional (3-D) printing and...

Image courtesy of Philips Healthcare

Feature | Molecular Imaging | July 01, 2019 | By Sharvari Rale
Diagnostic procedures have always been a cornerstone of early prognosis and patient triaging.
TeraRecon Receives FDA Clearance for Northstar AI Results Explorer
Technology | Artificial Intelligence | June 20, 2019
Advanced visualization and artificial intelligence (AI) technology provider TeraRecon has successfully completed a U.S...